Publication date: Jun 14, 2026
Rapid and reliable detection of respiratory infections can lead to better treatment decisions in outpatient environments. Numerous multiplex tests for diagnosis of respiratory infections are available for point-of-care (PoC) testing environments. This study evaluated the analytical and clinical performance of two commercially available tests: the Xpert Xpress CoV-2/Flu/RSV plus test and the Biofire Spotfire R/ST Panel Mini for the detection of SARS-CoV-2, Influenza (Flu)A, FluB, and Respiratory Syncytial Virus (RSV). Analytical sensitivity was evaluated using samples contrived at analyte concentrations near the tests’ limits of detection. Additionally, 1577 clinical NPS specimens from patients of all ages were tested based on standard of care (SoC) results to evaluate relative clinical performance. Total percent agreement was calculated. Analytical performance of both assays aligned with data provided in the tests’ respective package inserts. Clinical performance for all analytes was similar, with overall percent agreements of (SARS-CoV-2 98. 7%, FluA 98. 9%, FluB 99. 9%, RSV 98. 9%). The Xpert Xpress CoV-2/Flu/RSV plus test and Biofire Spotfire R/ST Panel Mini are highly accurate.
| Concepts | Keywords |
|---|---|
| Analyte | Influenza |
| Biofire | Multiplex molecular assay |
| Influenza | Respiratory syncytial virus |
| Outpatient | Respiratory virus |
| Reliable | RT-PCR |
| SARS-CoV-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | respiratory infections |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | Influenza |
| disease | MESH | NPS |